KRAS and neoplasm: In this preclinical study, we demonstrated for the first time that the addition of fulvestrant to the active avutometinib/defactinib combination may significantly increase tumor control when compared to fulvestrant alone or compared to the combination of avutometinib plus defactinib in a KRAS wild-type LGSOC PDX model resistant to chemotherapy and aromatase inhibitor.